Author + information
- Parth Parikh,
- Kinjal Banerjee,
- Amar Krishnaswamy,
- Christopher Bajzer,
- Ravi Nair,
- Russell Raymond,
- E. Murat Tuzcu and
- Samir Kapadia
Although randomized controlled trials have compared the outcomes of drug eluting stents (DES), there is lack of data beyond 5 years. We compared the outcomes of DES based on drug polymer at 9 and 12 years.
Consecutive patients undergoing a DES placement from 1/2005-9/2016 at Cleveland Clinic were included utilizing data from a prospectively entered registry. Primary outcome was target lesion revascularization (TLR) based on data from the registry, and secondary outcome was all-cause mortality.
After propensity matching, a total of 9,459 patients were included with 16,482 lesions stented (44.6% everolimus, 30.2% sirolimus and 25.2% paclitaxel). At baseline, mean age was 65.7 years, with 28% females and 39% diabetics. Compared to everolimus, TLR was more frequent in sirolimus (HR 1.32, CI 1.15-1.52) and paclitaxel (HR 1.32, CI 1.14-1.52) DES. There was no difference in TLR between paclitaxel and sirolimus (HR 1.00, CI 0.88-1.14) (Fig 1a). Everolimus showed significantly higher survival compared to Paclitaxel and Sirolimus. There was no difference in mortality between Paclitaxel and Sirolimus (Fig 1b).
Everolimus DES had significantly lower TLR and mortality compared to sirolimus and paclitaxel on long term follow up. There was no significant difference in TLR and mortality in lesions stented with paclitaxel compared to sirolimus DES in the long-term. This study provides important insight into the 9- and 12-year outcomes of DES in the real world scenario.
Poster Hall, Hall F
Saturday, March 16, 2019, 10:00 a.m.-10:45 a.m.
Session Title: Interventional Cardiology: Coronary Intervention: Devices 1
Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices
Presentation Number: 1104-045
- 2019 American College of Cardiology Foundation